FXYD3 and neoplasm: It has been reported that FXYD2 (Gaut et al., 2013), FXYD3 (Kayed et al., 2006; Widegren et al., 2009) and FXYD5 (Sato et al., 2003) are up-regulated in several types of tumors, leading to accelerated tumor growth and progression (Grzmil et al., 2004; Ino et al., 2002).